Cornely Oliver A, Vehreschild Jörg-Janne, Ullmann Andrew J
First Department of Internal Medicine, Hematology/Oncology/Infectious Diseases, University Hospital of Cologne, Köln, Germany.
Curr Opin Infect Dis. 2006 Dec;19(6):565-70. doi: 10.1097/QCO.0b013e328010851d.
This is a clinical review on the current role of polyene antifungals in the treatment of invasive fungal infections. It is timely and relevant because the number of new antifungals being developed has never been greater than today. In addition to re-examining the landmark clinical trials of the past, the more recent findings are put into perspective. The past year has been particularly rich in clinical trials.
The main topics of this review are invasive candidiasis, invasive aspergillosis, and the so-called rare fungal infections: zygomycosis, fusariosis, cryptococcosis and histoplasmosis.
Practical implications of the recent developments are the almost complete replacement of amphotericin B deoxycholate by lipid-based formulations; antifungal efficacy without compromising safety; and treatment choices for infections previously considered untreatable.
这是一篇关于多烯类抗真菌药物在侵袭性真菌感染治疗中当前作用的临床综述。鉴于目前正在研发的新型抗真菌药物数量空前之多，此综述具有及时性和相关性。除重新审视过去具有里程碑意义的临床试验外，还对最新研究结果进行了全面考量。过去一年临床试验成果颇丰。
本综述的主要主题为侵袭性念珠菌病、侵袭性曲霉病以及所谓的罕见真菌感染：接合菌病、镰刀菌病、隐球菌病和组织胞浆菌病。
近期进展的实际意义在于脂质体制剂几乎完全取代了去氧胆酸盐两性霉素B；在不影响安全性的情况下具备抗真菌疗效；以及为先前认为无法治疗的感染提供了治疗选择。
